C Diff Drug Development

Pfizer’s vaccine for Clostridium difficile (C. diff) looks like it may join a growing list of candidates that

Drugmakers working on treatments for C. difficile infections are having a bad week. Just one day after Pfizer reported its C. difficile vaccine candidate did not hit the primary endpoint in a Phase III study, Finch Therapeutics is finding itself in a similar position. The biotech said Tuesday its microbiome

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that...

Pfizer Inc (NYSE: PFE) announced data from the CLOVER Phase 3 trial evaluating Clostridioides difficile vaccine candidate to prevent C. difficile infection (CDI). Initial...

When firms reach FDA approval then go under, "the problem must be the market."

Pre-specified secondary endpoint showed 0-11 vaccine to placebo case split for medically attended C. difficile infection (CDI), corresponding to 100% vaccine efficacy Median CDI duration was 1 versus 4 days and mean duration was 3 versus 16 days comparing vaccine to placebo, corresponding to a 75% and 80% reduction in disease episode, respectively, in vaccinated people Vaccine was very well tolerated and showed a favorable safety profile Trial did not meet its pre-specified primary endpoint of prevention of primary CDI, however, for all CDI cases recorded at 14 days post dose 3, vaccine efficacy was 49%, 47% and 31% up to 12 months, 24 months and at final analysis, respectively Company evaluating next steps for C. difficile vaccine program in coordination with regulatory agencies Pfizer Inc. (NYSE:PFE) today announced results from the CLOVER trial ( CLO stridium difficile V accine E fficacy T R ial), a pivotal Phase 3 study evaluating its Clostridioides difficile ( C. difficile )

(HealthDay)—An investigational microbiome therapeutic composed of purified Firmicutes spores, SER-109, is superior to placebo for treatment of recurrent Clostridioides difficile infection, according ...

SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop

Join us to tackle one of the most important challenges of our time: antimicrobial resistance (AMR)! The Castagner Lab is developing non-antibiotic approaches against the Clostridioides difficile pa…

Nature Medicine - Multi-modal profiling reveals major alterations in colonic B cells in patients with ulcerative colitis, including reduced clonal diversity of plasma cells, and suggests that...

A stool-based enema composed of a broad variety of microbes (RBX2660, Rebiotix/Ferring) was up to 84% effective in reducing recurrent emClostridioides difficile/em infection in a study of more than 720 adults with rCDI. br /p /p

Following a period of bearish conditions, investors are anxiously awaiting the next big rally. A return to normal levels would help revitalize investor portfolios and confidence following a difficult month for the markets. However, the return to bullish conditions may come sooner than many may believe –especially for those companies that navigated the situation wisely. […]

Tweetable abstract Treating Clostridioides difficile infection with miRNAs alone or combined with live biotherapeutic products may augment therapeutic efficacy and help counteract drug resistance in the future.

TNP-2198, a stable conjugate of a rifamycin pharmacophore and a nitroimidazole pharmacophore, has been designed, synthesized, and evaluated as a novel dual-targeted antibacterial agent for the treatment of microaerophilic and anaerobic bacterial infections. TNP-2198 exhibits greater activity than a …

An investigational oral microbiome treatment was 70% more effective than placebo in preventing CDI recurrence within 8 weeks of treatment. https://t.co/9o8lQcFGkw @DrPaulGastro #cdiff— Gastro & Endo News (@gastroendonews) February 17, 2022

Original Article from The New England Journal of Medicine — SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection

An experimental three-day therapy that involves introducing Firmicutes spores into the gut may reduce the risk of Clostridium difficile reinfection by nearly 70%, a phase III trial shows. The treatment, known as SER-109, appeared to be more effective in patients under 65, which the US researchers say is “clinically important” given their increased risk of recurrent disease and hospital readmission. Most patients had a sustained clinical response 'out to about six months', researchers say.

Big pharma and investors focusing on other segments despite the need for new therapeutics

Clostridium difficile is an important zoonotic intestinal pathogen, which is widely present in humans and a variety of animals. The ST11 type C. difficile is one of the most widespread and harmful subtypes in the world. As a large country in pig farming, China lacks efficient methods f …

In this phase 2a study, ten of ten patients achieved SCC, demonstrated favorable pharmacokinetics, minimal adverse events, and beneficial microbiome and bile acids results. These results support continued clinical development.

Acurx Pharmaceuticals, Inc. announced today that results of its positive Phase 2a clinical trial have been published in Clinical Infectious Diseases.

Bacteriophages represent a promising option for the treatment of Clostridioides difficile (formerly Clostridium difficile) infection (CDI), which at present relies on conventional antibiotic therapy. The specificity of bacteriophages should prevent dysbiosis of the colonic microbiota associated with …

Join us to tackle one of the most important challenges of our time: antimicrobial resistance (AMR)! The Castagner Lab is developing non-antibiotic approaches against the Clostridioides difficile pa…

4D Pharma has programs for treating irritable bowel syndrome (IBS) but also for cancer. 4D researchers have found, for example, that short chain fatty acids from M. massiliensis enhance the production of effector cytokines in CD8+ cells. Even more interestingly, 4D’s MRx0518 live biotherapeutic, is currently under investigation as an adjuvant treatment (with Keytruda) for a variety of cancers.

Adjuvant combinations may enhance or broaden the expression of immune responses to vaccine antigens. Information on whether established Alum type adjuvants can be combined with experimental CD1d ligand adjuvants is currently lacking. In this study, we used a murine Clostridioides difficile im …

The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.